Evidence Table 5a. Adequacy of Reporting in Observational Studies in Sickle Cell Disease

Author, yearStudy descriptionInclusion or exclusion criteria describedKey characteristics of participants describedCompletion RateInstrument ValidatedValidity DiscussedReliability DiscussedQ Score
de Montalembert, 1999 552 0 1 0 0 0 18
Schultz, 2003 532 1 0 0 0 0 14

blank cells indicate “not applicable” response by one reviewer

Q = quality

From: Appendix C: Evidence Tables

Cover of Hydroxyurea for the Treatment of Sickle Cell Disease
Hydroxyurea for the Treatment of Sickle Cell Disease.
Evidence Reports/Technology Assessments, No. 165.
Segal JB, Strouse JJ, Beach MC, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.